<DOC>
	<DOCNO>NCT00576706</DOCNO>
	<brief_summary>To prove efficacy safety Mucosta® ( Rebamipide ) non-inferior Cytotec® ( Misoprostol ) , term prevention NSAID-induced gastric ulcer .</brief_summary>
	<brief_title>PReventive Efficacy Safety rEbamipide Nsaid Induced Mucosal Toxicity</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Rebamipide</mesh_term>
	<mesh_term>Misoprostol</mesh_term>
	<criteria>1 . Signed write informed consent inform clinical trial 2 . Males females 19 year age 3 . Intake brand NSAIDs half daily dose least previous 4 week . 1 . Necessary proceed concomitant treatment epileptic medication , antichollinergics , prokinetics , sucralfate 2 . Presence history allergic drug reaction follow medication ; rebamipide , Misoprostol , NSAIDs designate protocol</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Patients rheumatoid arthritis , osteoarthritis , ankylose spondylitis arthritis-like disease require continuous NSAIDs therapy</keyword>
</DOC>